Browsing by Author "Kaur, Amarjeet"

Now showing 1 - 4 of 4
  • Thumbnail Image
    Item
    Anesthetic Nuances In A Hypertrophic Cardiomyopathy Patient For Laparoscopic Abdominoperineal Resection
    (Atharva Scientific Publications, 2019-11) Kaur, Amarjeet; Kaur, Manbir; Singh, Amanjot; Jain, Aarushi
    Hypertrophic cardiomyopathy is a complex cardiac disease with unique pathophysiologic characteristics and a great diversity of morphologic, functional, and clinical features. It is characterized by a massive asymmetrical hypertrophy of the myocardium. Clinical features range from an absence of symptoms to sudden death. We report a rare case of a 57-year-old male presenting with a history of constipation for 3 months, weight loss and fatigue for 3 months, and blood in stools for 1 month. He was diagnosed with a carcinoma rectum. He was planned for abdominoperineal resection by laparoscopic approach. Aim of this case report is to discuss the challenging technical nuances of anesthetic management of a patient with hypertrophic cardiomyopathy posted for laparoscopic surgery
  • Thumbnail Image
    Item
    Efficacy and safety of pegylated IFN alfa 2b alone or in combination with ribavirin in thalassemia major with chronic hepatitis C.
    (2010-03) Sood, Ajit; Sobti, Praveen; Midha, Vandana; Singla, Dinesh; Kaur, Amarjeet; Kaushal, Sandeep; Sood, Neena; Mittal, Rasham; Puri, Sandeep
    Background Treatment of HCV infection in patients with thalassemia major (TM) is limited by the lack of large clinical trials and concerns about ribavirin-induced hemolysis. Methods We conducted a prospective, randomized, openlabel study to determine efficacy and tolerability of pegylatedinterferon alfa 2b (1.5 μg/kg/week) alone (group A) or with ribavirin (12–15 mg/kg/day; group B) in patients with TM and chronic HCV infection. Patients with genotype 1 or 4 HCV were treated for 48 weeks and those with genotype 3 or 2 HCV for 24 weeks. Early viral response (EVR; after 12 weeks of treatment), end-of-treatment virological response (ETR) and sustained virological response (SVR; 6 months after stopping therapy) were assessed. Results Of 40 patients, 20 each were allocated to the two treatment groups. EVR rates in group A and B were 15 (75%) and 18 (90%), respectively. ETR occurred in 17/20 (85%) patients in each group. SVR occurred in 8 (40%) patients in group A and 14 (70%) in group B. Blood transfusion requirements increased in one patient in group A and four patients in group B. One patient in group A had severe sepsis and one in group B had nephrotic syndrome. Two patients in each group required reduction in drug dose. Conclusions In patients with TM and chronic HCV infection, pegylated interferon alfa 2b and ribavirin combination therapy achieves a higher SVR rate than pegylated interferon alone, and is well tolerated except for an increase in blood transfusion requirement.
  • Thumbnail Image
    Item
    How sustained is sustained viral response in patients with hepatitis C virus infection.
    (2010-05) Sood, Ajit; Midha, Vandana; Mehta, Varun; Sharma, Sarit; Mittal, Rasham; Thara, Amandeep; Sood, Neena; Kaur, Amarjeet
    Background Sustained virological response (SVR) is achieved in a high proportion of patientswith chronic hepatitis C infection, particularly those with genotype 2 or 3 HCV infection. However, data on long-term durability of virological response in patients who achieve SVR are limited. Aim To evaluate the long-term durability of virological response in patients who have achieved SVR with interferon-based combination therapy. Methods One hundred patients with chronic HCV infection who had obtained SVR after IFN and ribavirin combination therapy were followed up for up to 8 years with annual HCV RNA testing. Results During a followed up of 6 months to 8 years, 8 of 100 patients with initial SVR developed late relapse of HCV infection. Relapse was more common in patients who had cirrhosis (5/28 [18%] vs. (3/72 [4%] with no cirrhosis; p=0.037). Conclusion SVR is durable in most patients, but some patients do have late relapse; long term follow up may be particularly important in a subset of patients with HCV infection who have liver cirrhosis.
  • Thumbnail Image
    Item
    Role of risk of malignancy index 4 in evaluation of adnexal masses
    (Medip Academy, 2020-09) Kaur, Amarjeet; Sharma, Sujata; Singh, Sohan
    Background: The discrimination between benign and malignant adnexal masses is important for clinical management and surgical planning in such patients. Various combined methods of evaluation adnexal mass have also been proposed. Risk of malignancy index (RMI) is a combined parameter which is simple, preclinical and highly sensitive, and more specific. Risk of malignancy index 4 (RMI 4) is calculated as a product of ultrasound score (U)×menopausal score (M)×CA 125×tumor size. Objective of this study was to determine if the RMI (RMI 4) can distinguish between benign and malignant adnexal masses.Methods: A prospective study was conducted on 30 women with an adnexal mass presenting in the OPD and emergency and RMI-4 calculated. Cut off level of 450 was set to differentiate between benign and malignant mass.Results: In this study, the value of RMI-4 is less than 450 in 17 patients with benign disease and 3 patients with malignant disease. The value is more than 450 in 2 patients with benign disease and 8 patients with malignant disease. RMI-4 >450 had a sensitivity of 72.73% and specificity is 89.47%. The positive predictive value is 80% and negative predictive value is 85%. The p-value for RMI-4 in this study is 0.001 which is highly significant.Conclusions: RMI is a reliable, simple, easy to use and cost-effective method in differentiating benign from malignant adnexal masses.